Get the Stockscreener App
92.89
0.42%
0.39
After Hours:
92.89
Amedisys Inc stock is traded at $92.89, with a volume of 244.94K.
It is up +0.42% in the last 24 hours and up +0.30% over the past month.
Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, and high acuity care segment. The Home Health Segment provides skilled nurses, therapists, and aids to patients' homes throughout the United States; the Hospice segment operates many centers designed to provide comfort and support for terminally ill patients; and the High acuity care segment can deliver the essential elements of inpatient hospital, SNF care, and palliative care to patients in their homes. A majority of the company's revenue is derived from the Home Health segment.
See More
Previous Close:
$92.50
Open:
$92.64
24h Volume:
244.94K
Relative Volume:
0.67
Market Cap:
$3.05B
Revenue:
$2.32B
Net Income/Loss:
$82.93M
P/E Ratio:
36.86
EPS:
2.52
Net Cash Flow:
$203.54M
1W Performance:
+0.84%
1M Performance:
+0.30%
6M Performance:
-4.44%
1Y Performance:
+0.10%
1-Day Range:
$92.54
$93.00
1-Week Range:
$91.89
$93.00
52-Week Range:
$82.15
$98.95
Amedisys Inc Stock (AMED) Company Profile
Name
Amedisys Inc
Sector
Industry
Phone
(225) 292-2031
Address
3854 AMERICAN WAY, BATON ROUGE, LA
Compare AMED with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMED
Amedisys Inc
|
92.89 | 3.05B | 2.32B | 82.93M | 203.54M | 2.52 |
|
HCA
Hca Healthcare Inc
|
334.18 | 82.28B | 70.60B | 5.76B | 5.64B | 21.97 |
|
FMS
Fresenius Medical Care Ag Adr
|
24.78 | 14.54B | 20.87B | 715.14M | 1.67B | 1.2209 |
|
DVA
Davita Inc
|
149.83 | 13.14B | 12.67B | 827.68M | 1.42B | 9.27 |
|
THC
Tenet Healthcare Corp
|
127.75 | 12.48B | 20.97B | 3.13B | 2.39B | 31.21 |
|
UHS
Universal Health Services Inc
|
178.08 | 11.58B | 15.42B | 1.03B | 956.84M | 15.02 |
Amedisys Inc Stock (AMED) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-29-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-01-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-07-23 | Downgrade | Truist | Buy → Hold |
| Apr-21-23 | Initiated | Cantor Fitzgerald | Neutral |
| Mar-13-23 | Initiated | Barclays | Equal Weight |
| Oct-27-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Aug-02-22 | Downgrade | UBS | Neutral → Sell |
| Jun-29-22 | Initiated | Stifel | Hold |
| Jun-21-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-01-22 | Upgrade | UBS | Sell → Neutral |
| Feb-25-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Feb-25-22 | Reiterated | Credit Suisse | Outperform |
| Feb-25-22 | Reiterated | Oppenheimer | Outperform |
| Feb-25-22 | Reiterated | RBC Capital Mkts | Outperform |
| Feb-25-22 | Reiterated | Raymond James | Outperform |
| Feb-25-22 | Reiterated | Truist | Buy |
| Sep-27-21 | Initiated | SVB Leerink | Mkt Perform |
| Sep-24-21 | Initiated | UBS | Sell |
| Sep-10-21 | Initiated | Cowen | Market Perform |
| Aug-10-21 | Reiterated | The Benchmark Company | Buy |
| Aug-05-21 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-20-20 | Resumed | Barclays | Overweight |
| Jul-30-20 | Reiterated | The Benchmark Company | Buy |
| Jun-18-20 | Upgrade | The Benchmark Company | Hold → Buy |
| May-07-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Mar-09-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-17-20 | Initiated | Credit Suisse | Outperform |
| Nov-01-19 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-22-19 | Resumed | Stephens | Equal-Weight |
| Sep-17-19 | Initiated | Deutsche Bank | Buy |
| May-02-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Dec-14-18 | Initiated | Barclays | Equal Weight |
| Nov-16-18 | Initiated | UBS | Neutral |
| Oct-30-18 | Upgrade | The Benchmark Company | Hold → Buy |
| Jul-03-18 | Upgrade | BofA/Merrill | Neutral → Buy |
| Mar-19-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Nov-09-17 | Downgrade | The Benchmark Company | Buy → Hold |
| Nov-08-17 | Reiterated | Mizuho | Buy |
| Nov-02-17 | Upgrade | The Benchmark Company | Hold → Buy |
| Aug-21-17 | Initiated | BofA/Merrill | Neutral |
View All
Amedisys Inc Stock (AMED) Latest News
Oppenheimer moving to Perform from Not Rated on Amedisys - TipRanks
US Bancorp DE Boosts Holdings in Amedisys, Inc. (NASDAQ:AMED) - Defense World
Raymond James maintains Amedisys stock Market Perform rating By Investing.com - Investing.com Canada
Raymond James maintains Amedisys stock Market Perform rating - Investing.com
Amedisys, Inc. (NASDAQ:AMED) Shares Purchased by Bank of New York Mellon Corp - Defense World
Mutual of America Capital Management LLC Has $1.57 Million Stake in Amedisys, Inc. (NASDAQ:AMED) - Defense World
Amedisys, Inc. (NASDAQ:AMED) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Amedisys, Inc. to Host Earnings Call - ACCESS Newswire
Amedisys chief accounting officer sells $187,833 in stock By Investing.com - Investing.com South Africa
Amedisys chief accounting officer sells $187,833 in stock - Investing.com
Amedisys Executive Makes a Bold Stock Sale! - TipRanks
DOJ Fights Bid To Pause Piece Of Amedisys Merger Case - Law360
Amedisys (NASDAQ:AMED) Receives “Equal Weight” Rating from Stephens - Defense World
Amedisys motion to separate Section 7A claim should be denied, US DOJ says - MLex
Hospice Services Market Projected To Witness Substantial Growth, 2025-2032: AccentCare, Curo Health Services, - EIN News
Amedisys, Inc. (NASDAQ:AMED) Shares Sold by Principal Financial Group Inc. - Defense World
William Blair Has Negative Estimate for Amedisys Q1 Earnings - MarketBeat
Research Analysts Offer Predictions for Amedisys Q1 Earnings - Defense World
Decoding Amedisys Inc (AMED): A Strategic SWOT Insight - GuruFocus.com
Amedisys Reports 2024 Financial Results Amid Merger Plans - TipRanks
Amedisys (NASDAQ:AMED) Posts Quarterly Earnings Results, Misses Estimates By $0.09 EPS - MarketBeat
Amedisys (NASDAQ:AMED) Issues Quarterly Earnings Results - MarketBeat
Amedisys Hold Rating: Mixed Performance and Cost Pressures Amid Regulatory Uncertainties - TipRanks
Amedisys Reports Home Health Care Growth Amid Shadow Of DOJ-UHG Lawsuit - Home Health Care News
Amedisys ticks lower as DOJ trial to block UnitedHealth deal set for Oct. 27 or later - MSN
Amedisys Sees Hospice Growth as DOJ-UnitedHealth Group Lawsuit Looms - Hospice News
Amedisys tells SEC several states have enacted ‘mini-Hart-Scott-Rodino laws’ - MLex
Amedisys (AMED) Reports Q4 Earnings: What Key Metrics Have to Say - MSN
AMEDISYS INC SEC 10-K Report - TradingView
Amedisys: Q4 Earnings Snapshot - mySA
Amedisys (AMED) Lags Q4 Earnings and Revenue Estimates - Yahoo Finance
Amedisys Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Amedisys Reports Q4 2024 Financial Results Amid Merger Plans - TipRanks
Earnings Flash (AMED) AMEDISYS INC. Reports Q4 Adjusted EPS $0.96, vs. FactSet Est of $1.05 - Marketscreener.com
Amedisys Reports Fourth Quarter and Year End 2024 Financial Results - The Manila Times
Amedisys Earnings: How $66M in Merger Expenses Shaped Their Bottom Line - StockTitan
Homecare Rehabilitation Service Market Projected To Witness Substantial Growth, 2025-2032: Genesis HealthCare, - EIN News
UnitedHealth-Amedisys referral to magistrate judge sparks settlement hopes - MLex
UnitedHealth-Amedisys case with US DOJ referred to judge for settlement talks - MLex
Amedisys, Inc. (NASDAQ:AMED) Shares Acquired by Rhumbline Advisers - Defense World
Amedisys (AMED) Q2 Earnings Top Estimates, Gross Margin Down - MSN
Short Interest in Amedisys, Inc. (NASDAQ:AMED) Rises By 7.1% - MarketBeat
ABC Arbitrage SA Invests $2.52 Million in Amedisys, Inc. (NASDAQ:AMED) - MarketBeat
United Health-Amedisys trial in US DOJ challenge 'tentatively' set for Oct. 27 - MLex
AMED: 3 Up-and-Coming Healthcare Providers Enhancing Patient Care - StockNews.com
State of Alaska Department of Revenue Increases Stock Holdings in Amedisys, Inc. (NASDAQ:AMED) - MarketBeat
Brokerages Set Amedisys, Inc. (NASDAQ:AMED) Target Price at $100.75 - MarketBeat
Amedisys' (AMED) "Equal Weight" Rating Reaffirmed at Stephens - MarketBeat
Amedisys (AMED) Projected to Post Earnings on Wednesday - MarketBeat
Amedisys Inc Stock (AMED) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):